Research map: The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions

Back to the article

Papers in this map

  1. CAR T cell immunotherapy for human cancer · Carl H. June · 2018 · 3261 citations · Cited by this paper
  2. Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis · Kathryn Rose Owen · 2023 · 30 citations · Related
  3. CAR-T cell therapy: current limitations and potential strategies · Robert C. Sterner · 2021 · 2926 citations · Cited by this paper
  4. Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study · 2026 · Related
  5. Innate or Adaptive Immunity? The Example of Natural Killer Cells · Eric D. Vivier · 2011 · 2820 citations · Cited by this paper
  6. Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15 · 2026 · Related
  7. Adoptive cell transfer as personalized immunotherapy for human cancer · Steven A. Rosenberg · 2015 · 2547 citations · Cited by this paper
  8. Route of BCG administration determines success · 2026 · Related
  9. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes · Steven A. Rosenberg · 1986 · 1897 citations · Cited by this paper
  10. Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study · 2026 · Related
  11. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy · Hans Raskov · 2020 · 1770 citations · Cited by this paper
  12. Immunological insights into why pertussis continues to be endemic · 2026 · Related
  13. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1 · Paul F. Robbins · 2011 · 1640 citations · Cited by this paper
  14. Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China · 2026 · Related
  15. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial · Hussein A. Tawbi · 2017 · 1480 citations · Cited by this paper
  16. Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation · 2026 · Related
  17. Long-term outcomes following CAR T cell therapy: what we know so far · Kathryn M. Cappell · 2023 · 1414 citations · Cited by this paper
  18. Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants · 2026 · Related
  19. Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition · Eric O. Long · 2013 · 1247 citations · Cited by this paper
  20. Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions · 2026 · Related
  21. Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy · Gerald Paul Rosen · 1982 · 1102 citations · Cited by this paper
  22. Targeting natural killer cells in cancer immunotherapy · Camille Guillerey · 2016 · 1102 citations · Cited by this paper
  23. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells · Luca Gattinoni · 2005 · 1065 citations · Cited by this paper
  24. Targeting neoantigens to augment antitumour immunity · Mark M. Yarchoan · 2017 · 1055 citations · Cited by this paper
  25. Neoantigens: promising targets for cancer therapy · Na Xie · 2023 · 1004 citations · Cited by this paper
  26. Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma · Nabil M. Ahmed · 2015 · 1002 citations · Cited by this paper
  27. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas · Robbie G. Majzner · 2022 · 832 citations · Cited by this paper
  28. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells · Brian Cameron · 2013 · 700 citations · Cited by this paper
  29. NK cell-based immunotherapy for malignant diseases · Min Cheng · 2013 · 638 citations · Cited by this paper
  30. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma · Maartje W. Rohaan · 2022 · 577 citations · Cited by this paper
  31. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma · Francesca Del Bufalo · 2023 · 569 citations · Cited by this paper
  32. Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing · Françoise Ducimetière · 2011 · 559 citations · Cited by this paper
  33. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity · Purnima Bhat · 2017 · 525 citations · Cited by this paper
  34. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial · David Marín · 2024 · 503 citations · Cited by this paper
  35. Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability · Cyrille J. Cohen · 2006 · 480 citations · Cited by this paper
  36. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. · Michael A. Simon · 1986 · 470 citations · Cited by this paper
  37. From bench to bedside: the history and progress of CAR T cell therapy · Aroshi Mitra · 2023 · 465 citations · Cited by this paper
  38. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy · Gavin M. Bendle · 2010 · 450 citations · Cited by this paper
  39. Cytokines in cancer immunity and immunotherapy · Mark John Smyth · 2004 · 419 citations · Cited by this paper

Source: OpenAlex (CC0)